XTX Topco’s Regencell Bioscience RGC Stock Holding History

XTX Topco’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,081	Closed	-$317K	–	4289
2025 Q4	$317K	Sell	15,081 -23,654	-61%	-$385K	0.01%	2018
2025 Q3	$598K	Buy	+38,735	New	+$556K	0.03%	936

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

XTX Topco's RGC Position: Q1 2026 in Review

XTX Topco sold out of Regencell Bioscience (RGC) in Q1 2026, closing a stake of 15,081 shares — an estimated $317K sold.

XTX Topco first reported a position in RGC in Q3 2025 and held it in 2 quarters. The position peaked at $598K in Q3 2025. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

XTX Topco reported no remaining Regencell Bioscience position as of Q1 2026 after selling out during the quarter.
XTX Topco sold 15,081 Regencell Bioscience shares in Q1 2026, an estimated $317K.
XTX Topco first reported a position in Regencell Bioscience in Q3 2025 and held it in 2 quarters.
XTX Topco's Regencell Bioscience position peaked at $598K in Q3 2025.
31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.